MedTrace Logo

Evaluating High Flow Humidification Therapy in Patients With Cystic Fibrosis

NCT02129803 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-01-06

Study results available
· View outcomes & findings →

Summary

This study is a single center, randomized pilot study to evaluate the clinical effectiveness of nasal high flow 20LPM humidification therapy in subjects with Cystic Fibrosis.

Conditions

Interventions

DEVICE

High-Flow, 20 LPM (via Optiflow cannula)

Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.

DEVICE

Low FLow, 5 LPM (via Optiflow cannula)

standard humidified wall medical air.

Sponsors & Collaborators

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Bruce K Rubin, MD · Virginia Commonwealth University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2019-05-29
Completion
2019-05-29
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02129803 on ClinicalTrials.gov